• Tiada Hasil Ditemukan

Experimental Protocols Used in the Study

N/A
N/A
Protected

Academic year: 2022

Share "Experimental Protocols Used in the Study "

Copied!
33
0
0

Tekspenuh

(1)

142

A ppend ix A

Sociodemographics of OSCC patients where FFPE specimens were obtained and details of the RNA quantity and quality. NoSam- ples Block#Diagnosi s SiteAge of sample month

Tiss ue dep- th mm

Area mm2

Tum- our volume mm3

RNA yield ng/ul

Total RNA yield ng

Ct differ- ence

% genes with sig- nificant signal

Pattern of differ- entiationAgeGenderRaceHabitsStaging 1B01D273/06 COSCCB240.04391.6128.13842.41277.7Moderate49FIndianBQT4N0M0 2B02D119/06(vi)bOSCCB280.0637.82.3208.76260.11461.4Well to moderate61FMalayNo HabitT1N0M0 3B03D474/04- A (VII)aOSCCB450.04411.674.22224.51072.9Moderate50FIndianBQT4N1M0 4B04D108/06OSCCB280.0411.90.5702099.11273.7Moderate66MIndianNAMissing data 5B0520/04OSCCB540.113.11.3112.13363.31278.1Moderate57FIndianNAT4 N1 Mx 6B06520/05OSCCB320.1333.3403.112091. 51187.8Moderate73FIndianSmoke, BQT2N0M0 7B07154/03OSCCB600.119.21.9266.67997.11290NA67LChines e Smoke, Alcohol T4 N2a Mx 8B0876/06OSCCB290.141.94.2446.813403. 71190.4Moderate74FIndianBQT4 N2c Mx 9B09296/06OSCCB240.124.42.4285.38560.21088.4Well67FIndianAlcohol, BQT4 N1 Mx 10B10237/06OSCCB240.1373.7144.24326.31181.5Well69FIndianBQT4 N1 Mx 11B11190/06OSCCB260.152.45.2890.126703. 61275.7Well to moderate53LMalayNo HabitT4 N3 M0 12B12138/04OSCCB510.144.94.591.52743.51286.9Well72FIndianNAT4 N0 Mx 13B13551/04OSCCB430.122.72.3346.610399. 21333.5Moderate48FIndianAlcohol, BQT4N1M0 14B14120/06OSCCB280.117.61.8321.796511190Moderate76MIndianSmoke, Alcohol, BQT4 N1 Mx 15B15366/06OSCCB230.120.92.1189.45683.21183.5Well67FIndianAlcohol, BQT4 N1 Mx 16B1662/06OSCCB290.135.13.5172.55175.31183.7Well52FIndianBQT1N0M0 17B1784/05OSCCB400.1313.134.21025.41218.9Moderate74FIndianBQT1N0M0 18B18303/05OSCCB360.119.9254.716411285.1Well67FIndianBQT4N0M0 19B20334/03OSCCB570.130.53.1405.512163. 81285.9Well72FIndianNAMissing data 20B2155/04OSCCB530.115.91.6185.35560.21280.5Moderate47FIndianBQT4 N1 Mx 21B22558/04OSCCB430.118.11.82848520.61384.1Well22FIndianBQT4 N0 M0 22B23335/03OSCCB570.111.51.2373.711209. 81285.5Moderate55MIndianSmoke, BQT1 N0M0 23B24D137/04-B1OSCCB510.04562.238.111431268.7Moderate63FIndianBQT2N2BM0 24BD25D113/04 AOSCCB520.06120.725.5763.8NANAModerate66FIndianBQT4N2BMx 25BD26D241/05 I(vi)bOSCCB360.04200.89.7292.2NANAModerate38FChines e Smoke, AlcoholT1N2AM0 26BD27D406/04-1a(ii)OSCCB460.04602.418.9566.4NANAModerate58FChines e No HabitT2N0M0 27BD28D251/06-B(iii) OSCCB240.120213.2395.1NANAPapillary variant 66FIndianBQT1N0Mx 28BD29139/05OSCCB390.130322.8685.2NANANA65FIndianBQT2N0M0

(2)

143

NoSam- ples Block#DiagnosisSiteAge of sample month Tissue depth mm Area mm2Tum-our volume mm3

RNA yield ng/ul Total RNA yield ngCt differ- ence

% genes with sig- nificant signal

Pattern of differ- entiationAgeGenderRace HabitsStaging 29BD30212/05OSCCB380.1252.527.4820.5NANANA59FIndianBQT4N0M0 30BD3148/05OSCCB420.14043.9116.1NANANA50MIndianBQT4N0M0 1AM01D118/04 b(i)OSCCG520.06100662.21867.21758.4Moderate51FIndianBQT4N0M0 2AM02D422/04 B5 (ii) OSCCG450.061006209.56283.51472.7Moderate41MMalaySmoke T2N2BM0 3AM03D88/05 A(v)aOSCCG400.1666.642.112631655Well54MMalaySmoke T4N0M0 4AM04D55/05OSCCG410.1121.2170.95125.51386.5Poor 76MIndianSmoke, AlcoholT2N0M0 5AM05D83/07OSCCG160.1151.5219.365791080.7Well67MMalayNo HabitT4N0M0 6AM06D392/05-1OSCCG350.1202224.16723.61187.3Well75FIndianBQMissing data 7AM07D407/06OSCCG220.1121.21624860.61187.1Poor 54MIndianSmoke, AlcoholT4N2bMx 8AM08D135/06-T(i)OSCCG270.1505236.87103.11376.1Well71FIndianBQT4N2BM0 9AM09D134/07-8(i)a OSCCG150.113513.53249719.7981.5Well49MMalaySmoke T4N0M0 10AM10D472/06- B1OSCCG450.1505185.555651970.5Well58FIndianBQT3N0M0 11AM11D146/04-A T(ii) OSCCG510.1444.4222.56674.41666.7Well80FIndianBQT4N0M0 12AM12D577/06OSCCG190.1404362.210867.21180.5Poor 71FIndianAlcohol, BQMissing data 13AM13D38/07OSCCG180.130334510349.41464.3Poor 71FIndianAlcohol, BQMissing data 14AM14D98/07OSCCG160.1191.9379.711391.6886.1NA57MIndianNAMissing data 15AM15D182/06OSCCG260.1282.8190.35708.71467.3Well to moderate72FIndianSmoke, Alcohol, BQT1N2BM0 16AM1612 / -03OSCCG660.1161.6199.65988.61633.3Moderate64MChinese NAMissing data 17AM1749/02OSCCG690.1181.8269.48081.11614.5Well76MMalayNAMissing data 18AM18D442/06OSCCG210.1202342.810283.41476.9Well66FIndianBQT4N0M0 19AMD19D498/06OSCCG200.11001023.2695.4NANAWell58FIndianBQMissing data 20AMD20D472/04 B2 (vi)OSCCG00.06804.86.3188.4NANANA58FIndianBQT3N0M0 1T01D264/06-A1OSCCT240.137.23.764.91945.51273.5Moderate59FSikhBQT1N2BM0 2T02D250/05D3OSCCT360.19.61175.35259.31584.9Moderate71MIndianAlcoholT1N0M0 3T03D70/06OSCCT290.136.83.7142.64276.8877.3Moderate72MIndianSmoke, AlcoholMissing data 4T04B973/05OSCCT00.01800.84012001574.1Moderate NAMissing data 5T04(5) D33/06OSCCT290.1252.5133.13991.51273.9Moderate65MChinese Smoke Missing data 6T05(6) D33/04OSCCT540.1181.869.120731177.3Moderate53MMalayNAMissing data 7T06(7) 541/05OSCCT310.110.91.1291.48740.51586.1Moderate69MIndianSmoke, Alcohol, BQT1N0M0 8T07(8) D446/05OSCCT340.1202623.118693.91281.1Well46MChinese Smoke, Alcohol, BQMissing data 9T08(9) 537/05OSCCT310.1121.2352.910586.11480.1Moderate45MChinese AlcoholT4N1M1 10T09(10) D241/06OSCCT240.145.44.5400.4120121478.9Moderate to well65MChinese Smoke Missing data

Appendix A, continued

Rujukan

DOKUMEN BERKAITAN

Compound C1 was exposed to several human cancer cell lines including breast adenocarcinoma cell lines, MCF-7 and MDA-MB-231, ovarian adenocarcinoma cell lines, Skov3 and

In examining the effect of sonication cycle time on the effectiveness of in-situ ultrasonication in increasing the rate of filtration, experiment was initially conducted

The cell s.u.'s are taken into account individually in the estimation of s.u.'s in distances, angles and torsion angles; correlations between s.u.'s in cell parameters are only

The cell s.u.'s are taken into account individually in the estimation of s.u.'s in distances, angles and torsion angles; correlations between s.u.'s in cell parameters are only

antiproliferative activity ofiC 50 2.82 Jlg/ml was shown by the ethanol crude extract treated HeLa cancer cell lines.. HeLa cells (most potent cell lines) was then treaed with

The supernatant was discarded and the cell pellet was resuspended in 1 ml of 20 % supplemented medium before being transferred to a 25 ml tissue culture flask

Once the sodium azide was dissolved completely (swirls the cylinder gently if necessary), distilled water was added to bring the volume up to the final volume of 10 ml.

Two cell lines were used for the cytotoxic study using MTS assay (Section 2.4.4.6).The cell lines used were Hep G2 and T- 47D, each representing known cells originating from